作为选择性HDAC1/2抑制剂的β-carboline衍生物的设计,合成和抗瘤活性研究
Zhiya Wang1, Limeng Wu2, Kaisi Yang2
1Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People's Republic of China; School of Pharmacy, China Medical University, Shenyang 110122, People's Republic of China.
Bioorganic chemistry
|July 24, 2025
概括
基于β-卡博林的新型HDAC抑制剂,特别是ZWZH-21,通过向HDAC1/2.2,对结直肠癌产生强大的抗瘤作用. 这种化合物有效地抑制癌细胞的生长,迁移,并诱导亡,具有有希望的疗效和低毒性.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 药用化学 医学化学
- 在瘤学瘤学.
背景情况:
- 希斯脱乙酶 (HDAC) 抑制剂是具有抗瘤潜力的关键表观遗传调节剂.
- 目前的HDAC抑制剂在结直肠癌治疗中面临挑战,原因是选择性问题和毒性.
研究的目的:
- 开发基于β-卡博林的新型HDAC1/2双抑制剂,用于结直肠癌治疗.
- 评估化合物ZWZH-21作为潜在的抗癌剂的疗效和安全性.
主要方法:
- 在体外抗增殖试验和酶抑制试验.
- 西方斑点分析和细胞热转移试验 (CETSA).
- 在小鼠模型中进行的体内异种移植研究.
主要成果:
- ZWZH-21对结直肠癌细胞系 (HCT116,SW480) 具有较低的IC50值,表现出显著的抗增殖活性.
- 该化合物强烈抑制了HDAC1/2,具有高选择性和增加了基因素乙化.
- ZWZH-21抑制了瘤生长,迁移,诱导了亡,并且在体内没有可观察到的毒性.
结论:
- ZWZH-21是新型HDAC抑制剂开发的有希望的化合物.
- 该化合物表现出显著的抗瘤疗效和在结直肠癌治疗中有利的安全性.
相关概念视频
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Structure-Activity Relationships and Drug Design
1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K


